Multifaceted Comparison of Ultrasound-guided Ablation and Laparoscopic Adrenalectomy for A
The purpose of this study is to retrospectively and prospectively analyze the efficacy and safety of ultrasound-guided radiofrequency ablation and laparoscopic adrenalectomy in the treatment of aldosterone-producing adenoma (APA). It is planned to retrospectively collect 30 patients with adrenal radiofrequency ablation
| Condition(s) | Aldosterone-producing Adenoma, Radiofrequency Ablation |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The purpose of this study is to retrospectively and prospectively analyze the efficacy and safety of ultrasound-guided radiofrequency ablation and laparoscopic adrenalectomy in the treatment of aldosterone-producing adenoma (APA). It is planned to retrospectively collect 30 patients with adrenal radiofrequency ablation for APA and 15 patients with age - and sex-matched laparoscopic adrenalectomy for APA in our hospital from January 2020 to June 2024, and continue to follow up for 3 years. |
| Who can participate | Inclusion Criteria: 1. APA was confirmed with unilateral lesions; 2. Benign tumor without adrenal metastasis and endovascular tumor embolus; 3. Receive ultrasound-guided adrenal RFA treatment or laparoscopic resection, and sign the informed consent for surgery; 4. Age ≥ 18; 5. Age ≥ 40 years old should meet the following criteria: blood potassium ≤3.5mmol/L; PAC≥20ng/dL; PRC≤5μIU/mL; A unilateral adrenal nodule of 10mm or more was completely normal on the opposite side. Exclusion Criteria: 1. Bilateral adrenal diseases; 2. Multiple adrenal tumors; 3. Other adrenal diseases, such as adrenal hyperplasia, Cushing's syndrome, pheochromocytoma, etc.; 4. Imaging suggests that the tumor may be difficult to reach; 5. Imaging showed potential malignant adrenal tumor; 6. Pregnant and/or planning a p |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Third Affiliated Hospital, Sun Yat-Sen University |
| Locations | Guangzhou, Guangdong, China |
| Start date | 2020-01-01 |
| NCT ID | NCT05991856 |
| Official listing | https://clinicaltrials.gov/study/NCT05991856 |